Vir Biotechnology, Inc. Common Stock
VIRVir Biotechnology, Inc. is a biotechnology company focused on developing and commercializing innovative therapies to treat and prevent infectious diseases. Founded with a mission to enhance immune responses and improve healthcare outcomes, Vir leverages cutting-edge science in immunology and antibody technologies to address global health challenges, including viral infections such as influenza, HIV, and COVID-19.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| December 3, 2010 | $0.03 | 2010-11-03 | 2010-11-05 |
| September 17, 2010 | $0.03 | 2010-08-25 | 2010-08-27 |
| June 11, 2010 | $0.03 | 2010-05-12 | 2010-05-14 |
| March 19, 2010 | $0.03 | 2010-03-03 | 2010-03-05 |
| December 1, 2009 | $0.03 | 2009-11-06 | 2009-11-10 |
Dividends Summary
- Consistent Payer: Vir Biotechnology, Inc. Common Stock has rewarded shareholders with 13 dividend payments over the past 3 years.
- Total Returned Value: Investors who held VIR shares during this period received a total of $0.33 per share in dividend income.
- Latest Payout: The most recent dividend of $0.03/share was paid 5706 days ago, on December 3, 2010.
- Yield & Schedule: VIR currently pays dividends quarterly with an annual yield of 1.06%.
- Dividend Growth: Since 2007, the dividend payout has grown by 0.0%, from $0.03 to $0.03.
- Dividend Reliability: VIR has maintained or increased its dividend for 13 consecutive payments.
Company News
Superstring Capital Management established a new $5.82 million position in Vir Biotechnology by acquiring 730,548 shares in Q1 2026. The investment appears to be a bet on upcoming clinical catalysts rather than current financials, with Vir expecting Phase 3 hepatitis delta data in Q4 2026 and pivotal Phase 3 oncology trials in 2027. Despite being...
A new generation of immuno-oncology therapies targeting historically immunotherapy-resistant solid tumors like prostate and pancreatic cancer is advancing rapidly through clinical trials in 2026. Four distinct mechanistic approaches—including NK cell engagers, oncolytic virus immune-primers, and tumor microenvironment-conditional antibodies—a...
Vir Biotechnology CEO Marianne De Backer sold 72,559 shares worth $664,350 on April 6, 2026, representing 6.76% of her holdings. The sale aligns with her historical selling patterns and appears to be income supplementation rather than a loss of confidence. The company has shown positive momentum with encouraging clinical trial results for VIR-550...
U.S. stock futures rose on Tuesday following Monday's sell-off triggered by AI-related economic concerns and a viral 'Global Intelligence Crisis' report. Market sentiment remains cautious amid Trump's tariff threats and geopolitical tensions. Key movers include Keysight Technologies surging 16% on strong earnings, Vir Biotechnology jumping 63% on...
Alnylam Pharmaceuticals, a biotech company focused on RNA interference (RNAi) therapies, has shown significant growth since its 2004 IPO. The company has multiple approved drugs for rare diseases and a promising pipeline of potential treatments across various medical conditions.
